Main menu

Miragen Therapeutics said this week that it has formed a sponsored research and licensing arrangement with the University of Colorado focused on microRNA therapeutics.

Under the sponsored-research portion of the deal, Miragen will fund the analysis of miRNA and gene-expression changes from a study of beta blocker effects on cardiac remodeling and gene expression conducted at the University of Colorado Cardiovascular Institute at the UC Denver School of Medicine.